KOL Corner: Amy Ellis Discusses Value-Based Cancer Rehab With Amanda Hodges

The Orphan Drug Act in the Modern Drug Pricing Era

Ateequllah Hayat, PhD, discusses epigenetic rewiring, biomarkers, and emerging strategies to overcome lapatinib resistance in HER2+ breast cancer.

ACOs Improve Primary, Preventive Care Delivery for Medicare Beneficiaries

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Listen

Patient-centered care. | Image Credit_ Fabio Balbi - stock.adobe.com

Reflecting on 15 Years of Health IT Evolution and What’s Next: Nate C. Apathy, PhD

Beneficiaries in ACOs receive significantly higher rates of primary and preventive services, signaling value-based care’s impact on quality and chronic disease management.

January 27th 2026

PBM Reforms Signed Into Law, Reshaping Medicare Part D Drug Pricing Transparency

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Listen

Congress advances sweeping PBM transparency reforms tied to Medicare Part D as part of a broader spending package. | Image Credit: PBMs_MQ-Illustrations.jpeg

Pulmonary Fibrosis and Sexual Health: A Q&A With Na’ama Avitzur, MD

A spending bill advancing PBM reforms aims to delink Medicare Part D compensation from drug rebates and improve pricing transparency.

In this Q&A, Na’am Avitzur, MD, discusses how pulmonary fibrosis impacts sexual health and why addressing quality of life matters.

February 2nd 2026

New Molecular Drivers of HER2 Breast Cancer Resistance: A Q&A With Ateequllah Hayat, PhD

A European Respiratory Journal study shows pulmonary fibrosis affects sexual function and quality of life, calling for open clinician-patient conversations.

Related Content

The Orphan Drug Act in the Modern Drug Pricing Era

Ateequllah Hayat, PhD, discusses epigenetic rewiring, biomarkers, and emerging strategies to overcome lapatinib resistance in HER2+ breast cancer.

ACOs Improve Primary, Preventive Care Delivery for Medicare Beneficiaries

Policy strategist Kristi Martin discusses how the Orphan Drug Act reshapes rare disease treatment and drug-pricing challenges.

Listen

Reflecting on 15 Years of Health IT Evolution and What’s Next: Nate C. Apathy, PhD

Beneficiaries in ACOs receive significantly higher rates of primary and preventive services, signaling value-based care’s impact on quality and chronic disease management.

January 27th 2026

PBM Reforms Signed Into Law, Reshaping Medicare Part D Drug Pricing Transparency

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Listen

Pulmonary Fibrosis and Sexual Health: A Q&A With Na’ama Avitzur, MD

A spending bill advancing PBM reforms aims to delink Medicare Part D compensation from drug rebates and improve pricing transparency.

February 2nd 2026